Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent

Beta-lapachone (beta-Lp) derived from the Lapacho tree is a potentially novel anticancer agent currently under clinical trials. Previous studies suggested that redox activation of beta-Lp catalyzed by NAD(P)H:quinone oxidoreductase 1 (NQO1) accounted for its killing of cancer cells. However, the exa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Toxicology and applied pharmacology 2014-12, Vol.281 (3), p.285-293
Hauptverfasser: Li, Jason Z., Ke, Yuebin, Misra, Hara P., Trush, Michael A., Li, Y. Robert, Zhu, Hong, Jia, Zhenquan
Format: Artikel
Sprache:eng
Schlagworte:
EPR
ROS
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 293
container_issue 3
container_start_page 285
container_title Toxicology and applied pharmacology
container_volume 281
creator Li, Jason Z.
Ke, Yuebin
Misra, Hara P.
Trush, Michael A.
Li, Y. Robert
Zhu, Hong
Jia, Zhenquan
description Beta-lapachone (beta-Lp) derived from the Lapacho tree is a potentially novel anticancer agent currently under clinical trials. Previous studies suggested that redox activation of beta-Lp catalyzed by NAD(P)H:quinone oxidoreductase 1 (NQO1) accounted for its killing of cancer cells. However, the exact mechanisms of this effect remain largely unknown. Using chemiluminescence and electron paramagnetic resonance (EPR) spin-trapping techniques, this study for the first time demonstrated the real-time formation of ROS in the redox activation of beta-lapachone from cancer cells mediated by mitochondria and NQO1 in melanoma B16–F10 and hepatocellular carcinoma HepG2 cancer cells. ES936, a highly selective NQO1 inhibitor, and rotenone, a selective inhibitor of mitochondrial electron transport chain (METC) complex I were found to significantly block beta-Lp meditated redox activation in B16–F10 cells. In HepG2 cells ES936 inhibited beta-Lp-mediated oxygen radical formation by ~80% while rotenone exerted no significant effect. These results revealed the differential contribution of METC and NQO1 to beta-lapachone-induced ROS formation and cancer cell killing. In melanoma B16–F10 cells that do not express high NQO1 activity, both NOQ1 and METC play a critical role in beta-Lp redox activation. In contrast, in hepatocellular carcinoma HepG2 cells expressing extremely high NQO1 activity, redox activation of beta-Lp is primarily mediated by NQO1 (METC plays a minor role). These findings will contribute to our understanding of how cancer cells are selectively killed by beta-lapachone and increase our ability to devise strategies to enhance the anticancer efficacy of this potentially novel drug while minimizing its possible adverse effects on normal cells. •Both isolated mitochondria and purified NQO1 are able to generate ROS by beta-Lp.•The differential roles of mitochondria and NQO1 in mediating redox activation of beta-Lp•In cancer cells with low NQO1 expression, mitochondria play a critical role in beta-Lp redox activation.•In cancer cells with high NQO1 activity, redox activation of beta-Lp is primarily mediated by NQO1.
doi_str_mv 10.1016/j.taap.2014.10.012
format Article
fullrecord <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_22439932</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041008X14003731</els_id><sourcerecordid>1647016773</sourcerecordid><originalsourceid>FETCH-LOGICAL-c561t-596a85e28022e4ac58fab20b789ff4f015fb803fdba010b7138a50f934a5066f3</originalsourceid><addsrcrecordid>eNp9kc-KFDEQxoMo7uzqC3iQgAge7LGSTv8DL7K4KqwugoK3UJ2uuBl6Om2SGdxn8KVN06PePBVUfl9V6vsYeyJgK0DUr3bbhDhvJQiVG1sQ8h7bCOjqAsqyvM82AEoUAO23M3Ye4w4AOqXEQ3YmK6VaUM2G_fpI5hYnF5MzPKbD4Chyb7nByVDghsaR713y5tZPQ3BYcJwG_unzjSj2NDhMNPBAg__J0SR3xOT8tOh7SliMOOMipJcc-ewTTcnhON7xyR9pzJPy0nUPfs9vj9gDi2Okx6d6wb5evf1y-b64vnn34fLNdWGqWqSi6mpsK5ItSEkKTdVa7CX0TdtZqyyIyvYtlHboEURui7LFCmxXqlzq2pYX7Nk61-erdTQuZQ-MnyYySUupyq4rZaZerNQc_I8DxaT3Li5-4ET-ELWoVZNTaJoyo3JFTfAxBrJ6Dm6P4U4L0EtUeqeXqPQS1dLLUWXR09P8Q5-t_Cv5k00Gnp8AjAZHG7JVLv7jOmhytiJzr1eOsmdHR2E5ibKtgwvLRYN3__vHb7MIso8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1647016773</pqid></control><display><type>article</type><title>Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Li, Jason Z. ; Ke, Yuebin ; Misra, Hara P. ; Trush, Michael A. ; Li, Y. Robert ; Zhu, Hong ; Jia, Zhenquan</creator><creatorcontrib>Li, Jason Z. ; Ke, Yuebin ; Misra, Hara P. ; Trush, Michael A. ; Li, Y. Robert ; Zhu, Hong ; Jia, Zhenquan</creatorcontrib><description>Beta-lapachone (beta-Lp) derived from the Lapacho tree is a potentially novel anticancer agent currently under clinical trials. Previous studies suggested that redox activation of beta-Lp catalyzed by NAD(P)H:quinone oxidoreductase 1 (NQO1) accounted for its killing of cancer cells. However, the exact mechanisms of this effect remain largely unknown. Using chemiluminescence and electron paramagnetic resonance (EPR) spin-trapping techniques, this study for the first time demonstrated the real-time formation of ROS in the redox activation of beta-lapachone from cancer cells mediated by mitochondria and NQO1 in melanoma B16–F10 and hepatocellular carcinoma HepG2 cancer cells. ES936, a highly selective NQO1 inhibitor, and rotenone, a selective inhibitor of mitochondrial electron transport chain (METC) complex I were found to significantly block beta-Lp meditated redox activation in B16–F10 cells. In HepG2 cells ES936 inhibited beta-Lp-mediated oxygen radical formation by ~80% while rotenone exerted no significant effect. These results revealed the differential contribution of METC and NQO1 to beta-lapachone-induced ROS formation and cancer cell killing. In melanoma B16–F10 cells that do not express high NQO1 activity, both NOQ1 and METC play a critical role in beta-Lp redox activation. In contrast, in hepatocellular carcinoma HepG2 cells expressing extremely high NQO1 activity, redox activation of beta-Lp is primarily mediated by NQO1 (METC plays a minor role). These findings will contribute to our understanding of how cancer cells are selectively killed by beta-lapachone and increase our ability to devise strategies to enhance the anticancer efficacy of this potentially novel drug while minimizing its possible adverse effects on normal cells. •Both isolated mitochondria and purified NQO1 are able to generate ROS by beta-Lp.•The differential roles of mitochondria and NQO1 in mediating redox activation of beta-Lp•In cancer cells with low NQO1 expression, mitochondria play a critical role in beta-Lp redox activation.•In cancer cells with high NQO1 activity, redox activation of beta-Lp is primarily mediated by NQO1.</description><identifier>ISSN: 0041-008X</identifier><identifier>EISSN: 1096-0333</identifier><identifier>DOI: 10.1016/j.taap.2014.10.012</identifier><identifier>PMID: 25448047</identifier><identifier>CODEN: TXAPA9</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>60 APPLIED LIFE SCIENCES ; Activation, Metabolic - drug effects ; Animals ; Antineoplastic agents ; Antineoplastic Agents, Phytogenic - antagonists &amp; inhibitors ; Antineoplastic Agents, Phytogenic - metabolism ; Antineoplastic Agents, Phytogenic - pharmacology ; BENZOQUINONES ; Beta-lapachone ; Biological and medical sciences ; Cancer cells ; CELL KILLING ; Cell Line, Tumor ; CHEMILUMINESCENCE ; Chemotherapy ; CLINICAL TRIALS ; ELECTRON SPIN RESONANCE ; Electron Transport Complex I - antagonists &amp; inhibitors ; Electron Transport Complex I - metabolism ; Enzyme Inhibitors - pharmacology ; EPR ; HEPATOMAS ; Humans ; Indolequinones - pharmacology ; Medical sciences ; MELANOMAS ; Mice ; MITOCHONDRIA ; Mitochondria - drug effects ; Mitochondria - enzymology ; Mitochondria - metabolism ; Mitochondrial electron transport chain ; NAD(P)H Dehydrogenase (Quinone) - antagonists &amp; inhibitors ; NAD(P)H Dehydrogenase (Quinone) - metabolism ; Naphthoquinones - antagonists &amp; inhibitors ; Naphthoquinones - metabolism ; Naphthoquinones - pharmacology ; Neoplasm Proteins - antagonists &amp; inhibitors ; Neoplasm Proteins - metabolism ; Neoplasms - drug therapy ; Neoplasms - enzymology ; Neoplasms - metabolism ; NQO1 ; Oxidation-Reduction - drug effects ; OXIDES ; OXYGEN ; PEROXIDASES ; Pharmacology. Drug treatments ; PHOSPHATES ; Prodrugs - chemistry ; Prodrugs - metabolism ; Prodrugs - pharmacology ; RADICALS ; Reactive Oxygen Species - metabolism ; Reverse Transcriptase Inhibitors - chemistry ; Reverse Transcriptase Inhibitors - metabolism ; Reverse Transcriptase Inhibitors - pharmacology ; ROS ; Rotenone - pharmacology ; SUPEROXIDE DISMUTASE ; Toxicology</subject><ispartof>Toxicology and applied pharmacology, 2014-12, Vol.281 (3), p.285-293</ispartof><rights>2014 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c561t-596a85e28022e4ac58fab20b789ff4f015fb803fdba010b7138a50f934a5066f3</citedby><cites>FETCH-LOGICAL-c561t-596a85e28022e4ac58fab20b789ff4f015fb803fdba010b7138a50f934a5066f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.taap.2014.10.012$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=29070081$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25448047$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22439932$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Jason Z.</creatorcontrib><creatorcontrib>Ke, Yuebin</creatorcontrib><creatorcontrib>Misra, Hara P.</creatorcontrib><creatorcontrib>Trush, Michael A.</creatorcontrib><creatorcontrib>Li, Y. Robert</creatorcontrib><creatorcontrib>Zhu, Hong</creatorcontrib><creatorcontrib>Jia, Zhenquan</creatorcontrib><title>Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent</title><title>Toxicology and applied pharmacology</title><addtitle>Toxicol Appl Pharmacol</addtitle><description>Beta-lapachone (beta-Lp) derived from the Lapacho tree is a potentially novel anticancer agent currently under clinical trials. Previous studies suggested that redox activation of beta-Lp catalyzed by NAD(P)H:quinone oxidoreductase 1 (NQO1) accounted for its killing of cancer cells. However, the exact mechanisms of this effect remain largely unknown. Using chemiluminescence and electron paramagnetic resonance (EPR) spin-trapping techniques, this study for the first time demonstrated the real-time formation of ROS in the redox activation of beta-lapachone from cancer cells mediated by mitochondria and NQO1 in melanoma B16–F10 and hepatocellular carcinoma HepG2 cancer cells. ES936, a highly selective NQO1 inhibitor, and rotenone, a selective inhibitor of mitochondrial electron transport chain (METC) complex I were found to significantly block beta-Lp meditated redox activation in B16–F10 cells. In HepG2 cells ES936 inhibited beta-Lp-mediated oxygen radical formation by ~80% while rotenone exerted no significant effect. These results revealed the differential contribution of METC and NQO1 to beta-lapachone-induced ROS formation and cancer cell killing. In melanoma B16–F10 cells that do not express high NQO1 activity, both NOQ1 and METC play a critical role in beta-Lp redox activation. In contrast, in hepatocellular carcinoma HepG2 cells expressing extremely high NQO1 activity, redox activation of beta-Lp is primarily mediated by NQO1 (METC plays a minor role). These findings will contribute to our understanding of how cancer cells are selectively killed by beta-lapachone and increase our ability to devise strategies to enhance the anticancer efficacy of this potentially novel drug while minimizing its possible adverse effects on normal cells. •Both isolated mitochondria and purified NQO1 are able to generate ROS by beta-Lp.•The differential roles of mitochondria and NQO1 in mediating redox activation of beta-Lp•In cancer cells with low NQO1 expression, mitochondria play a critical role in beta-Lp redox activation.•In cancer cells with high NQO1 activity, redox activation of beta-Lp is primarily mediated by NQO1.</description><subject>60 APPLIED LIFE SCIENCES</subject><subject>Activation, Metabolic - drug effects</subject><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents, Phytogenic - antagonists &amp; inhibitors</subject><subject>Antineoplastic Agents, Phytogenic - metabolism</subject><subject>Antineoplastic Agents, Phytogenic - pharmacology</subject><subject>BENZOQUINONES</subject><subject>Beta-lapachone</subject><subject>Biological and medical sciences</subject><subject>Cancer cells</subject><subject>CELL KILLING</subject><subject>Cell Line, Tumor</subject><subject>CHEMILUMINESCENCE</subject><subject>Chemotherapy</subject><subject>CLINICAL TRIALS</subject><subject>ELECTRON SPIN RESONANCE</subject><subject>Electron Transport Complex I - antagonists &amp; inhibitors</subject><subject>Electron Transport Complex I - metabolism</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>EPR</subject><subject>HEPATOMAS</subject><subject>Humans</subject><subject>Indolequinones - pharmacology</subject><subject>Medical sciences</subject><subject>MELANOMAS</subject><subject>Mice</subject><subject>MITOCHONDRIA</subject><subject>Mitochondria - drug effects</subject><subject>Mitochondria - enzymology</subject><subject>Mitochondria - metabolism</subject><subject>Mitochondrial electron transport chain</subject><subject>NAD(P)H Dehydrogenase (Quinone) - antagonists &amp; inhibitors</subject><subject>NAD(P)H Dehydrogenase (Quinone) - metabolism</subject><subject>Naphthoquinones - antagonists &amp; inhibitors</subject><subject>Naphthoquinones - metabolism</subject><subject>Naphthoquinones - pharmacology</subject><subject>Neoplasm Proteins - antagonists &amp; inhibitors</subject><subject>Neoplasm Proteins - metabolism</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - enzymology</subject><subject>Neoplasms - metabolism</subject><subject>NQO1</subject><subject>Oxidation-Reduction - drug effects</subject><subject>OXIDES</subject><subject>OXYGEN</subject><subject>PEROXIDASES</subject><subject>Pharmacology. Drug treatments</subject><subject>PHOSPHATES</subject><subject>Prodrugs - chemistry</subject><subject>Prodrugs - metabolism</subject><subject>Prodrugs - pharmacology</subject><subject>RADICALS</subject><subject>Reactive Oxygen Species - metabolism</subject><subject>Reverse Transcriptase Inhibitors - chemistry</subject><subject>Reverse Transcriptase Inhibitors - metabolism</subject><subject>Reverse Transcriptase Inhibitors - pharmacology</subject><subject>ROS</subject><subject>Rotenone - pharmacology</subject><subject>SUPEROXIDE DISMUTASE</subject><subject>Toxicology</subject><issn>0041-008X</issn><issn>1096-0333</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc-KFDEQxoMo7uzqC3iQgAge7LGSTv8DL7K4KqwugoK3UJ2uuBl6Om2SGdxn8KVN06PePBVUfl9V6vsYeyJgK0DUr3bbhDhvJQiVG1sQ8h7bCOjqAsqyvM82AEoUAO23M3Ye4w4AOqXEQ3YmK6VaUM2G_fpI5hYnF5MzPKbD4Chyb7nByVDghsaR713y5tZPQ3BYcJwG_unzjSj2NDhMNPBAg__J0SR3xOT8tOh7SliMOOMipJcc-ewTTcnhON7xyR9pzJPy0nUPfs9vj9gDi2Okx6d6wb5evf1y-b64vnn34fLNdWGqWqSi6mpsK5ItSEkKTdVa7CX0TdtZqyyIyvYtlHboEURui7LFCmxXqlzq2pYX7Nk61-erdTQuZQ-MnyYySUupyq4rZaZerNQc_I8DxaT3Li5-4ET-ELWoVZNTaJoyo3JFTfAxBrJ6Dm6P4U4L0EtUeqeXqPQS1dLLUWXR09P8Q5-t_Cv5k00Gnp8AjAZHG7JVLv7jOmhytiJzr1eOsmdHR2E5ibKtgwvLRYN3__vHb7MIso8</recordid><startdate>20141215</startdate><enddate>20141215</enddate><creator>Li, Jason Z.</creator><creator>Ke, Yuebin</creator><creator>Misra, Hara P.</creator><creator>Trush, Michael A.</creator><creator>Li, Y. Robert</creator><creator>Zhu, Hong</creator><creator>Jia, Zhenquan</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>OTOTI</scope></search><sort><creationdate>20141215</creationdate><title>Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent</title><author>Li, Jason Z. ; Ke, Yuebin ; Misra, Hara P. ; Trush, Michael A. ; Li, Y. Robert ; Zhu, Hong ; Jia, Zhenquan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c561t-596a85e28022e4ac58fab20b789ff4f015fb803fdba010b7138a50f934a5066f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>60 APPLIED LIFE SCIENCES</topic><topic>Activation, Metabolic - drug effects</topic><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents, Phytogenic - antagonists &amp; inhibitors</topic><topic>Antineoplastic Agents, Phytogenic - metabolism</topic><topic>Antineoplastic Agents, Phytogenic - pharmacology</topic><topic>BENZOQUINONES</topic><topic>Beta-lapachone</topic><topic>Biological and medical sciences</topic><topic>Cancer cells</topic><topic>CELL KILLING</topic><topic>Cell Line, Tumor</topic><topic>CHEMILUMINESCENCE</topic><topic>Chemotherapy</topic><topic>CLINICAL TRIALS</topic><topic>ELECTRON SPIN RESONANCE</topic><topic>Electron Transport Complex I - antagonists &amp; inhibitors</topic><topic>Electron Transport Complex I - metabolism</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>EPR</topic><topic>HEPATOMAS</topic><topic>Humans</topic><topic>Indolequinones - pharmacology</topic><topic>Medical sciences</topic><topic>MELANOMAS</topic><topic>Mice</topic><topic>MITOCHONDRIA</topic><topic>Mitochondria - drug effects</topic><topic>Mitochondria - enzymology</topic><topic>Mitochondria - metabolism</topic><topic>Mitochondrial electron transport chain</topic><topic>NAD(P)H Dehydrogenase (Quinone) - antagonists &amp; inhibitors</topic><topic>NAD(P)H Dehydrogenase (Quinone) - metabolism</topic><topic>Naphthoquinones - antagonists &amp; inhibitors</topic><topic>Naphthoquinones - metabolism</topic><topic>Naphthoquinones - pharmacology</topic><topic>Neoplasm Proteins - antagonists &amp; inhibitors</topic><topic>Neoplasm Proteins - metabolism</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - enzymology</topic><topic>Neoplasms - metabolism</topic><topic>NQO1</topic><topic>Oxidation-Reduction - drug effects</topic><topic>OXIDES</topic><topic>OXYGEN</topic><topic>PEROXIDASES</topic><topic>Pharmacology. Drug treatments</topic><topic>PHOSPHATES</topic><topic>Prodrugs - chemistry</topic><topic>Prodrugs - metabolism</topic><topic>Prodrugs - pharmacology</topic><topic>RADICALS</topic><topic>Reactive Oxygen Species - metabolism</topic><topic>Reverse Transcriptase Inhibitors - chemistry</topic><topic>Reverse Transcriptase Inhibitors - metabolism</topic><topic>Reverse Transcriptase Inhibitors - pharmacology</topic><topic>ROS</topic><topic>Rotenone - pharmacology</topic><topic>SUPEROXIDE DISMUTASE</topic><topic>Toxicology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Jason Z.</creatorcontrib><creatorcontrib>Ke, Yuebin</creatorcontrib><creatorcontrib>Misra, Hara P.</creatorcontrib><creatorcontrib>Trush, Michael A.</creatorcontrib><creatorcontrib>Li, Y. Robert</creatorcontrib><creatorcontrib>Zhu, Hong</creatorcontrib><creatorcontrib>Jia, Zhenquan</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>OSTI.GOV</collection><jtitle>Toxicology and applied pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Jason Z.</au><au>Ke, Yuebin</au><au>Misra, Hara P.</au><au>Trush, Michael A.</au><au>Li, Y. Robert</au><au>Zhu, Hong</au><au>Jia, Zhenquan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent</atitle><jtitle>Toxicology and applied pharmacology</jtitle><addtitle>Toxicol Appl Pharmacol</addtitle><date>2014-12-15</date><risdate>2014</risdate><volume>281</volume><issue>3</issue><spage>285</spage><epage>293</epage><pages>285-293</pages><issn>0041-008X</issn><eissn>1096-0333</eissn><coden>TXAPA9</coden><abstract>Beta-lapachone (beta-Lp) derived from the Lapacho tree is a potentially novel anticancer agent currently under clinical trials. Previous studies suggested that redox activation of beta-Lp catalyzed by NAD(P)H:quinone oxidoreductase 1 (NQO1) accounted for its killing of cancer cells. However, the exact mechanisms of this effect remain largely unknown. Using chemiluminescence and electron paramagnetic resonance (EPR) spin-trapping techniques, this study for the first time demonstrated the real-time formation of ROS in the redox activation of beta-lapachone from cancer cells mediated by mitochondria and NQO1 in melanoma B16–F10 and hepatocellular carcinoma HepG2 cancer cells. ES936, a highly selective NQO1 inhibitor, and rotenone, a selective inhibitor of mitochondrial electron transport chain (METC) complex I were found to significantly block beta-Lp meditated redox activation in B16–F10 cells. In HepG2 cells ES936 inhibited beta-Lp-mediated oxygen radical formation by ~80% while rotenone exerted no significant effect. These results revealed the differential contribution of METC and NQO1 to beta-lapachone-induced ROS formation and cancer cell killing. In melanoma B16–F10 cells that do not express high NQO1 activity, both NOQ1 and METC play a critical role in beta-Lp redox activation. In contrast, in hepatocellular carcinoma HepG2 cells expressing extremely high NQO1 activity, redox activation of beta-Lp is primarily mediated by NQO1 (METC plays a minor role). These findings will contribute to our understanding of how cancer cells are selectively killed by beta-lapachone and increase our ability to devise strategies to enhance the anticancer efficacy of this potentially novel drug while minimizing its possible adverse effects on normal cells. •Both isolated mitochondria and purified NQO1 are able to generate ROS by beta-Lp.•The differential roles of mitochondria and NQO1 in mediating redox activation of beta-Lp•In cancer cells with low NQO1 expression, mitochondria play a critical role in beta-Lp redox activation.•In cancer cells with high NQO1 activity, redox activation of beta-Lp is primarily mediated by NQO1.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>25448047</pmid><doi>10.1016/j.taap.2014.10.012</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0041-008X
ispartof Toxicology and applied pharmacology, 2014-12, Vol.281 (3), p.285-293
issn 0041-008X
1096-0333
language eng
recordid cdi_osti_scitechconnect_22439932
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects 60 APPLIED LIFE SCIENCES
Activation, Metabolic - drug effects
Animals
Antineoplastic agents
Antineoplastic Agents, Phytogenic - antagonists & inhibitors
Antineoplastic Agents, Phytogenic - metabolism
Antineoplastic Agents, Phytogenic - pharmacology
BENZOQUINONES
Beta-lapachone
Biological and medical sciences
Cancer cells
CELL KILLING
Cell Line, Tumor
CHEMILUMINESCENCE
Chemotherapy
CLINICAL TRIALS
ELECTRON SPIN RESONANCE
Electron Transport Complex I - antagonists & inhibitors
Electron Transport Complex I - metabolism
Enzyme Inhibitors - pharmacology
EPR
HEPATOMAS
Humans
Indolequinones - pharmacology
Medical sciences
MELANOMAS
Mice
MITOCHONDRIA
Mitochondria - drug effects
Mitochondria - enzymology
Mitochondria - metabolism
Mitochondrial electron transport chain
NAD(P)H Dehydrogenase (Quinone) - antagonists & inhibitors
NAD(P)H Dehydrogenase (Quinone) - metabolism
Naphthoquinones - antagonists & inhibitors
Naphthoquinones - metabolism
Naphthoquinones - pharmacology
Neoplasm Proteins - antagonists & inhibitors
Neoplasm Proteins - metabolism
Neoplasms - drug therapy
Neoplasms - enzymology
Neoplasms - metabolism
NQO1
Oxidation-Reduction - drug effects
OXIDES
OXYGEN
PEROXIDASES
Pharmacology. Drug treatments
PHOSPHATES
Prodrugs - chemistry
Prodrugs - metabolism
Prodrugs - pharmacology
RADICALS
Reactive Oxygen Species - metabolism
Reverse Transcriptase Inhibitors - chemistry
Reverse Transcriptase Inhibitors - metabolism
Reverse Transcriptase Inhibitors - pharmacology
ROS
Rotenone - pharmacology
SUPEROXIDE DISMUTASE
Toxicology
title Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T05%3A39%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mechanistic%20studies%20of%20cancer%20cell%20mitochondria-%20and%20NQO1-mediated%20redox%20activation%20of%20beta-lapachone,%20a%20potentially%20novel%20anticancer%20agent&rft.jtitle=Toxicology%20and%20applied%20pharmacology&rft.au=Li,%20Jason%20Z.&rft.date=2014-12-15&rft.volume=281&rft.issue=3&rft.spage=285&rft.epage=293&rft.pages=285-293&rft.issn=0041-008X&rft.eissn=1096-0333&rft.coden=TXAPA9&rft_id=info:doi/10.1016/j.taap.2014.10.012&rft_dat=%3Cproquest_osti_%3E1647016773%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1647016773&rft_id=info:pmid/25448047&rft_els_id=S0041008X14003731&rfr_iscdi=true